Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 4/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493702 | 0.82 | CA2 (0.44) | CA2CA1CA9HSD11B1 | |
| SCHEMBL12492703 | 0.81 | CA1 (0.39) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL12493430 | 0.80 | CA1 (0.41) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL12493250 | 0.72 | ALDH1A1 (0.42) | CA2CA1CA9CA12 | |
| SCHEMBL12494442 | 0.70 | ACP3 (0.40) | HSD11B1 | |
| SCHEMBL12699946 | 0.69 | HRH3 (0.47) | CA2 | |
| SCHEMBL12013619 | 0.69 | CYP1A2 (0.41) | CYP1A2ALOX5HSD11B1 | |
| SCHEMBL12493409 | 0.68 | CA1 (0.48) | CA2CA1CA9CA12F2 | |
| SCHEMBL15271118 | 0.66 | HTR2A (0.44) | CA2CA1CA9CA5A | |
| SCHEMBL12493471 | 0.66 | ADRB2 (0.41) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683702-B1 | NEW SUBSTITUTED PHENYL OXATHIAZINE DERIVATIVES, METHOD FOR THEIR MANUFACTURE, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR APPLICATION | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| EP-2683702-B1 | NEW SUBSTITUTED PHENYL OXATHIAZINE DERIVATIVES, METHOD FOR THEIR MANUFACTURE, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR APPLICATION | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| US-8809324-B2 | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof | SANOFI (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809324-B2 | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof | SANOFI (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809324-B2 | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof | SANOFI (FR) | 2014-08-19 | — | — | US | disclosed |
| EP-2683702-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345127-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2013-12-26 | — | — | US | disclosed |
| WO-2012120050-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120050-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345127-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SLC5A2, SLC5A1, GPR119 | CA2 1050/4885CA1 2926/4885CA9 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.